# Tissue Regeneration by Engineered Extracellular Vesicles

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2021 · $460,142

## Abstract

Summary
Worldwide stem cell therapy market is poised to grow at a compound annual growth rate (CAGR) of 39.5%
from 2015 to 2020, reaching US$330M by 2020. However, limitations such as: (1) ethical issues related to
embryonic stem cells, (2) difficulties related with the preservation of stem cells, and (3) recent research
findings that the structural contribution of stem cells to regenerated tissues is actually very small, are
starting to compromise the promised potential of stem-cell based therapies. Recent research has thus
shifted away from cell based therapy to a paracrine hypothesis, investigating the stimulating factors
released and received by cells, including: growth factors, cytokines, and extracellular vesicles (EVs; i.e.,
exosomes and microvesicles containing angiogenic factors, transcription factors, miRNAs). Work proposed
here will determine whether myeloid cells, i.e., can be engineered to differentiate (or trans-differentiate) into
desired non-myeloid lineages through an orchestrated engineering of EV exchange within our novel
biomaterials platform.

## Key facts

- **NIH application ID:** 10218210
- **Project number:** 5R01GM128991-03
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** James D. Bryers
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $460,142
- **Award type:** 5
- **Project period:** 2019-09-20 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10218210

## Citation

> US National Institutes of Health, RePORTER application 10218210, Tissue Regeneration by Engineered Extracellular Vesicles (5R01GM128991-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10218210. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*